Skip to main content
. 2023 Sep 29;12(19):2384. doi: 10.3390/cells12192384

Figure 5.

Figure 5

Assessment of PI3K-AKT pathway inhibitors with ZOL-1 combinatorial treatment. (A) Cell viability reduction of non-responder GS054 cells by various chemical AKT pathway inhibitors with and without ZOL-1 co-treatment. (B) Apoptotic cell death of non-responder GS054 cells induced by various chemical AKT pathway inhibitors with and without ZOL-1 co-treatment. (C) Western blot analysis of PI3K-AKT pathway intermediates in responder (GS025) and non-responder (GS054) cell lines upon treatment with pictilisib or MK2206 2HCl with or without ZOL-1 co-treatment. (D) ZOL-1 titer in responder and non-responder cell lines with or without treatment with pictilisib or MK2206 HCl. Student’s t-test: p-value < 0.05 (*), p < 0.001 (**), p < 0.0001 (***).